Results 31 to 40 of about 1,772,527 (156)

Hypomethylating agents for urologic cancers

open access: yes, 2011
Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now
Hahn, Noah M   +11 more
core   +1 more source

MPP8 Facilitates DNA DSB Repair via NHEJ to Promote Chemoresistance of TNBC Independent of Methyl‐H3K9 Binding

open access: yesAdvanced Science, EarlyView.
Chemoresistance is often linked to elevated DNA repair. MPP8 is found to promote breast cancer chemoresistance as a novel NHEJ accessory factor independent of its epigenetic functions. Through multiple protein interactions, MPP8 facilitates association of DNAPK and ligase complexes to promote DNA repair progression.
Rupa Kumari, Jia Fang
wiley   +1 more source

A Machine Learning Model of Response to Hypomethylating Agents in Myelodysplastic Syndromes [PDF]

open access: yes, 2022
Hypomethylating agents (HMA) prolong survival and improve cytopenias in individuals with higher-risk myelodysplastic syndrome (MDS). Only 30-40% of patients, however, respond to HMAs, and responses may not occur for more than 6 months after HMA ...
Parmentier, Anne   +19 more
core   +2 more sources

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia

open access: yesHaematologica, 2020
In older patients with acute myeloid leukemia, the more frequent presence of biologically inherent therapy-resistant disease and increased comorbidities translate to poor overall survival and therapeutic challenges. Optimal front-line therapies for older
Chetasi Talati   +11 more
doaj   +1 more source

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes

open access: yes, 2011
Over the last decade, treatment approaches for patients with myelodysplastic syndromes (MDS) have improved significantly. Treatment of MDS is tailored to the specific risk characteristics of the patient.
Guillermo Garcia-Manero, Pierre Fenaux
core   +1 more source

Mitochondrial Quality Control in Degenerative Musculoskeletal Diseases: Signaling Networks and Therapeutic Landscapes

open access: yesAdvanced Science, EarlyView.
Mitochondrial quality control (MQC) collapse redefines osteoarthritis, intervertebral disc degeneration, and osteoporosis as disorders of organelle dysfunction. Damaged mitochondria leak mtDNA and metabolites, driving cGAS‐STING inflammation, epigenetic reprogramming, and metabolic memory.
Haiyang Gao   +7 more
wiley   +1 more source

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

open access: yesChinese Medical Journal, 2020
. Epigenetic regulation includes changes of DNA methylation and modifications of histone proteins and is essential for normal physiologic functions, especially for controlling gene expression.
Qing-Yu Xu, Li Yu, Peng Lyu
doaj   +1 more source

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents [PDF]

open access: yes, 2016
The cytidine analogues azacytidine and 5-aza-2′ -deoxycytidine (decitabine) are commonly used to treat myelodysplastic syndromes, with or without a myeloproliferative component.
Solier, Stéphanie   +45 more
core   +1 more source

TIPIN Couples Epigenetic Rewiring to EGFR Stabilization and Lenvatinib Resistance in Liver Cancer

open access: yesAdvanced Science, EarlyView.
DNA hypomethylation elevates TIPIN expression in liver cancer. TIPIN competes with E3 ligase c‐Cbl for the EGFR intracellular domain, inhibiting EGFR ubiquitination and lysosomal degradation to sustain oncogenic EGFR‐ ERK signaling. High TIPIN confers lenvatinib resistance, while TIPIN depletion restores drug sensitivity in liver cancer. ABSTRACT Aims:
Xing Jia   +15 more
wiley   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy